Association of serum digoxin concentration and outcomes in patients with heart failure

被引:464
作者
Rathore, SS
Curtis, JP
Wang, YF
Bristow, MR
Krumholz, HM
机构
[1] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Epidemiol, Sect Hlth Policy & Adm, New Haven, CT 06520 USA
[3] Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA
[4] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2003年 / 289卷 / 07期
关键词
D O I
10.1001/jama.289.7.871
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context The Digitalis Investigation Group (DIG) trial reported that digoxin provided no overall mortality benefit and only a modest reduction in hospitalizations among patients with heart failure and depressed left ventricular systolic function. The clinical outcomes associated with digoxin therapy at different serum concentrations in the DIG trial have not been assessed. Objective To assess variations in serum digoxin concentration (SDC) and their association with mortality and hospitalization in patients with heart failure. Design, Setting, and Patients Post hoc analysis of the randomized, double-blinded, place bo-controlled DIG trial, conducted from August 1991 to December 1995, with the main analysis restricted to men with a left ventricular ejection fraction of 45% or less (n = 3782). Patients randomly assigned to receive digoxin were divided into 3 groups based on SDC at 1 month (0.5-0.8 ng/mL, n=572; 0.9-1.1 ng/mL, n=322; and greater than or equal to1.2 ng/mL, n=277) And compared with patients randomly assigned to receive placebo (n = 2611). Main Outcome Measure All-cause mortality at a mean follow-up of 37 months. Results Higher SDCs were associated with increased crude all-cause mortality rates (0.5-0.8 ng/mL, 29.9%; 0.9-1.1 ng/mL, 38.8%; and greater than or equal to1.2 ng/mL, 48.0%; P=.006 for trend). Patients with SDCs of 0.5 to 0.8 ng/mL had a 6.3% (95% confidence, interval [01, 2.1%-10.5%) lower mortality rate compared with patients receiving placebo. Digoxin was not associated with a reduction in mortality among patients with SDCs of 0.9 to 1.1 ng/mL (2.6% increase; 95% CO,-3.0% to 8.3%), whereas patients with SDCs of 1.2 ng/mL and higher had an 11.8% (95% CI, 5.7%-18.0%) higher absolute mortality rate than patients receiving placebo. The association between SDC and mortality persisted after multivariable adjustment (SDC 0.5-0.8 ng/mL hazard ratio [HR] 0.80, 95% CI, 0.68-0.94; SDC 0.9-1.1 ng/mL HR 0.89, 95% CI, 0.74-1.08; SDC 1.2 ng/mL HR 1.16, 95% CI, 0.96-1.39; and HR of 1.00 [referent] for placebo). Conclusions Our findings demonstrate that higher SDCs were associated,with increased mortality and suggest that the effectiveness of digoxin therapy in men with heart failure and a left ventricular ejection fraction of 45% or less may be optimized in the SDC range of 0.5 to 0.8 ng/mL.
引用
收藏
页码:871 / 878
页数:8
相关论文
共 34 条
[1]  
Abernathy GT, 1996, CONTROL CLIN TRIALS, V17, P77
[2]   Clinical benefits of low serum digoxin concentrations in heart failure [J].
Adams, KF ;
Gheorghiade, M ;
Uretsky, BF ;
Patterson, JH ;
Schwartz, TA ;
Young, JB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (06) :946-953
[3]  
[Anonymous], 2002, American Journal of Kidney Diseases, V39, pS76, DOI DOI 10.1053/ajkd.2002.30944
[4]   LOW-DOSE INOTROPIC THERAPY FOR AMBULATORY HEART-FAILURE [J].
BRISTOW, MR ;
LOWES, BD .
CORONARY ARTERY DISEASE, 1994, 5 (02) :112-118
[5]  
BRISTOW MW, 2001, HEART DIS
[6]   A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure [J].
Cohn, JN ;
Goldstein, SO ;
Greenberg, BH ;
Lorell, BH ;
Bourge, RC ;
Jaski, BE ;
Gottlieb, SO ;
McGrew, F ;
DeMets, DL ;
White, BG .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (25) :1810-1816
[7]   DIGOXIN - A NEUROHORMONAL MODULATOR IN HEART-FAILURE [J].
GHEORGHIADE, M ;
FERGUSON, D .
CIRCULATION, 1991, 84 (05) :2181-2186
[8]   Digitalis Investigation Group (DIG) trial: A stimulus for further research [J].
Gheorghiade, M ;
Pitt, B .
AMERICAN HEART JOURNAL, 1997, 134 (01) :3-12
[9]   EFFECTS OF INCREASING MAINTENANCE DOSE OF DIGOXIN ON LEFT-VENTRICULAR FUNCTION AND NEUROHORMONES IN PATIENTS WITH CHRONIC HEART-FAILURE TREATED WITH DIURETICS AND ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS [J].
GHEORGHIADE, M ;
HALL, VB ;
JACOBSEN, G ;
ALAM, M ;
ROSMAN, H ;
GOLDSTEIN, S .
CIRCULATION, 1995, 92 (07) :1801-1807
[10]   ABC of heart failure -: Management:: digoxin and other inotropes, β blockers, and antiarrhythmic and antithrombotic treatment [J].
Gibbs, CR ;
Davies, MK ;
Lip, GYH .
BRITISH MEDICAL JOURNAL, 2000, 320 (7233) :495-498